Clinical and Demographic Characteristics of Older Inflammatory Bowel Disease Patients
There is limited data describing management of older Australians with inflammatory bowel disease (IBD). The prevalence of IBD in the elderly
is increasing due to an aging population and increasing overall incidence, which presents challenges in management due to comorbidities and
polypharmacy. The aim of the study was to describe demographic and clinical characteristics, and management of IBD in older patients. Around
100 consecutive patients (n = 100) aged above 60 years and attending the IBD outpatient clinic of Fiona Stanley Hospital from January 2019
were selected. Demographic and clinical information were compiled from the digital medical record. Around 59 patients had Crohn’s disease
(CD), 39 had ulcerative colitis (UC) and 2 unclassified IBD (IBD-U). Around 75% of patients had a Montreal classification recorded, which is a
recommended standard of care. For both CD and UC, no patients had onset of symptoms <17 years old, and the majority had symptom onset
after 40 years of age (CD—56%, UC—52%). Around 39% of CD patients had undergone at least one surgery, and 5% a second operation. No
UC patients had undergone surgery. 5’Aminosalicylates (59%), antitumor necrosis factor alpha (33%), thiopurines (22%), and vedolizumab
(11%) were the most common current treatments. Around 9% of patients were currently taking steroids while 36% had previously taken cor-
ticosteroids. Immunosuppressive events were recorded, if they occurred, after treatment with steroids, immunomodulatory or biologic agents.
Two patients had melanoma, 12 nonmelanoma skin cancer, 3 solid organ tumors (2 prostate adenocarcinoma and 1 bladder transitional cell
carcinoma), 3 latent tuberculosis, 1 myelodysplasia, and 1 septic arthritis. Around 14% of the patients had osteoporosis or osteopenia; 43%
of these had prior corticosteroid exposure; however, there was a low rate of bone densitometry. Most patients both with CD and UC were
diagnosed over 40. Biologics were the most common treatment category in keeping with the aim of achieving deep remission.
Show Abstract
